Abstract

Unfavourable pharmacokinetics is the major hurdle for the new chemical entity (NCE) to become a drug during the drug discovery and development process. Early evaluation of absorption, distribution, metabolism, and excretion (ADME) characteristics for the promising candidates not only speed up the drug development stages but also lower the attrition rate in clinical phases which can save resource and time. Furthermore, pharmacokinetic behavior is helpful for a better understanding of efficacy, toxicity, and safety. The present chapter deals with ADME information on chromene-based molecules, which have gained significant importance nowadays due to their wide range of pharmacological actions, including anticancer activities. Comprehensive ADME data based on the available information on in-vitro and in-vivo profiles will pave the way towards understanding for discovery and development of new therapeutics in this scaffold from bench to bedside.